JP2018527333A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527333A5
JP2018527333A5 JP2018504932A JP2018504932A JP2018527333A5 JP 2018527333 A5 JP2018527333 A5 JP 2018527333A5 JP 2018504932 A JP2018504932 A JP 2018504932A JP 2018504932 A JP2018504932 A JP 2018504932A JP 2018527333 A5 JP2018527333 A5 JP 2018527333A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
mospd2
composition according
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018504932A
Other languages
English (en)
Japanese (ja)
Other versions
JP6949818B2 (ja
JP2018527333A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/054584 external-priority patent/WO2017021857A1/en
Publication of JP2018527333A publication Critical patent/JP2018527333A/ja
Publication of JP2018527333A5 publication Critical patent/JP2018527333A5/ja
Application granted granted Critical
Publication of JP6949818B2 publication Critical patent/JP6949818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018504932A 2015-07-31 2016-07-29 運動精子ドメイン含有タンパク質2及びがん Active JP6949818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199571P 2015-07-31 2015-07-31
US62/199,571 2015-07-31
PCT/IB2016/054584 WO2017021857A1 (en) 2015-07-31 2016-07-29 Motile sperm domain containing protein 2 and cancer

Publications (3)

Publication Number Publication Date
JP2018527333A JP2018527333A (ja) 2018-09-20
JP2018527333A5 true JP2018527333A5 (https=) 2020-04-23
JP6949818B2 JP6949818B2 (ja) 2021-10-13

Family

ID=57942495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504932A Active JP6949818B2 (ja) 2015-07-31 2016-07-29 運動精子ドメイン含有タンパク質2及びがん

Country Status (10)

Country Link
US (2) US20190040150A1 (https=)
EP (2) EP3735977A1 (https=)
JP (1) JP6949818B2 (https=)
CN (1) CN108135933B (https=)
AU (1) AU2016303474B2 (https=)
CA (1) CA2991868C (https=)
ES (1) ES2839456T3 (https=)
IL (1) IL257260B (https=)
NZ (1) NZ738875A (https=)
WO (1) WO2017021857A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735981B1 (en) 2015-07-31 2023-08-30 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and inflammation
EP3735977A1 (en) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN112041336A (zh) * 2018-03-13 2020-12-04 脉管生物生长有限公司 针对mospd2和t细胞或nk细胞特异性分子的双特异性抗体
EP3597193A1 (en) 2018-07-16 2020-01-22 Universitat Autònoma de Barcelona Therapeutic use of afatinib in cancer
JP2023547026A (ja) * 2020-09-10 2023-11-09 バスキュラー バイオジェニックス リミテッド 運動精子ドメイン含有タンパク質2抗体およびその使用法
EP4313146A4 (en) * 2021-03-29 2025-04-02 ImmuneWalk Therapeutics, Inc. MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2, AND CD63
USD1105906S1 (en) * 2023-11-29 2025-12-16 Ufp Industries, Inc. Removable clip
USD1106811S1 (en) * 2023-11-29 2025-12-23 Ufp Industries, Inc. Removable clip

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
EP1414963A2 (en) * 2000-12-08 2004-05-06 Incyte Genomics, Inc. Lipid-associated molecules
WO2002063005A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules
AU2002309917A1 (en) * 2001-05-18 2002-12-03 Incyte Genomics, Inc. Lipid-associated molecules
US20040171009A1 (en) * 2001-05-18 2004-09-02 Tang Y. Tom Lipid-associated molecules
JP2005514007A (ja) * 2001-09-21 2005-05-19 インサイト・ゲノミックス・インコーポレイテッド 脂質関連分子
EP1463487B1 (en) 2001-12-19 2010-05-19 Research Development Foundation Liposomal delivery of vitamin e based compounds
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US20070218116A1 (en) 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
US20110257034A1 (en) * 2008-10-10 2011-10-20 Cornell University Methods for identifying genes which predict disease outcome for patients with colon cancer
EP2826370A3 (en) 2008-11-06 2015-04-08 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
DK2414542T3 (da) 2009-03-30 2017-11-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
AU2010260152A1 (en) 2009-06-15 2012-02-02 Cardiodx, Inc. Determination of coronary artery disease risk.
WO2011159951A2 (en) 2010-06-17 2011-12-22 Sanford-Burnham Medical Research Institute Targeting tumor associated macrophages using bisphosphonate-loaded particles
EP2420228A1 (en) 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
WO2012121679A1 (en) * 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
ES2758923T3 (es) * 2011-12-12 2020-05-07 Vascular Biogenics Ltd Tratamiento de esteatohepatitis no alcohólica
CN103592432B (zh) * 2013-10-15 2015-06-03 重庆市公安局 一种免疫磁珠分离精子与上皮细胞混合斑中精子的方法
EP3735977A1 (en) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
EP3735981B1 (en) 2015-07-31 2023-08-30 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and inflammation
JP2023547026A (ja) 2020-09-10 2023-11-09 バスキュラー バイオジェニックス リミテッド 運動精子ドメイン含有タンパク質2抗体およびその使用法
EP4313146A4 (en) 2021-03-29 2025-04-02 ImmuneWalk Therapeutics, Inc. MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2, AND CD63

Similar Documents

Publication Publication Date Title
JP2018527333A5 (https=)
US20220211870A1 (en) Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11945875B2 (en) Motile sperm domain containing protein 2 and cancer
US10966923B2 (en) Carrier-antibody compositions and methods of making and using the same
JP2022107690A (ja) 担体および抗体からなる組成物およびその製造および使用方法
US11241387B2 (en) Carrier-binding agent compositions and methods of making and using the same
JP2024513505A (ja) 腫瘍を治療するための組成物及び方法
JP7761490B2 (ja) 小細胞肺がんの併用療法用キノリン誘導体
CA3233721A1 (en) Methods of treating cancer and the pharmaceutical compositions thereof
JP7579284B2 (ja) セマフォリン4d遮断(sema4d)とdc1療法との併用療法
CN108883068B (zh) 乳癌治疗
KR20220133996A (ko) 암 및 암 전이를 치료하기 위한 병용 요법
JP2021517153A (ja) Mospd2およびt細胞またはnk細胞特異的分子に対する二重特異性抗体 電子出願された配列表の参照
JP2021517153A5 (ja) Mospd2およびt細胞またはnk細胞特異的分子に対する二重特異性抗体
WO2016191703A2 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer
RU2801828C2 (ru) Комбинированная терапия блокированием семафорина 4d (sema4d) и терапией дк1
HK40041339A (en) Motile sperm domain containing protein 2 and cancer
Zhou Development and Evaluation of LSR-and CD276-Targeted Therapies for Triple-Negative Breast Cancer
WO2024159105A1 (en) Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody
TW202535465A (zh) 抗cd147抗體與其他抗腫瘤劑之組合
JP2026514110A (ja) がんの処置および予防のための組合せ
Mao Monoclonal Antibody and Liposomal Nanoparticle-based Targeting Therapies for Chronic Lymphocytic Leukemia
OA18218A (en) Carrier-antibody compositions and methods of making and using the same
HK1254515B (en) Motile sperm domain containing protein 2 and cancer
HK1213444A1 (en) Cancer treatments